Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 34,300 shares, an increase of 18.7% from the March 15th total of 28,900 shares. Approximately 5.1% of the company’s shares are sold short. Based on an average trading volume of 122,800 shares, the short-interest ratio is presently 0.3 days.
Analyst Ratings Changes
Separately, StockNews.com started coverage on shares of Aptevo Therapeutics in a research report on Wednesday, April 10th. They set a “hold” rating on the stock.
Check Out Our Latest Report on APVO
Hedge Funds Weigh In On Aptevo Therapeutics
Aptevo Therapeutics Price Performance
Shares of APVO stock traded down $0.06 on Monday, reaching $0.78. 465,918 shares of the company were exchanged, compared to its average volume of 204,535. The company has a 50-day moving average of $5.15 and a 200-day moving average of $8.05. Aptevo Therapeutics has a one year low of $0.76 and a one year high of $91.96.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.
Read More
- Five stocks we like better than Aptevo Therapeutics
- How to Read Stock Charts for Beginners
- The Charles Schwab Company Can Hit New Highs
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- Quiet Period Expirations Explained
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.